5 Best Biotech Stocks to Invest In

3. Amicus Therapeutics, Inc. (FOLD)

The small-cap biotechnology company Amicus Therapeutics, Inc. (NASDAQ: FOLD) has been a member of Joseph Edelman’s portfolio since 2014. The hedge fund has benefitted strongly from its investment in Amicus Therapeutics. This is because Amicus shares jumped 150% in the last twelve months.    

Amicus is the third-largest stock holding of the veteran hedge fund manager, accounting for 5.10% of the overall portfolio. Amicus has generated third-quarter revenue of $67.44 million, up 38.3% year over year, and topped the consensus estimate by $2.56M.

John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “During the third quarter, we made tremendous progress advancing our mission for patients and are on track to achieve our 2020 key strategic priorities, including our global Fabry commercial launch, Pompe late-stage development program, and advancing our industry-leading gene therapy pipeline.”

Follow Amicus Therapeutics Inc. (NASDAQ:FOLD)